Machado Bruna Aparecida Souza, Hodel Katharine Valéria Saraiva, Fonseca Larissa Moraes Dos Santos, Mascarenhas Luís Alberto Brêda, Andrade Leone Peter Correia da Silva, Rocha Vinícius Pinto Costa, Soares Milena Botelho Pereira, Berglund Peter, Duthie Malcolm S, Reed Steven G, Badaró Roberto
SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), University Center SENAI/CIMATEC, Salvador 41650-010, Brazil.
Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador 40296-710, Brazil.
Vaccines (Basel). 2021 Nov 17;9(11):1345. doi: 10.3390/vaccines9111345.
In recent years, vaccine development using ribonucleic acid (RNA) has become the most promising and studied approach to produce safe and effective new vaccines, not only for prophylaxis but also as a treatment. The use of messenger RNA (mRNA) as an immunogenic has several advantages to vaccine development compared to other platforms, such as lower coast, the absence of cell cultures, and the possibility to combine different targets. During the COVID-19 pandemic, the use of mRNA as a vaccine became more relevant; two out of the four most widely applied vaccines against COVID-19 in the world are based on this platform. However, even though it presents advantages for vaccine application, mRNA technology faces several pivotal challenges to improve mRNA stability, delivery, and the potential to generate the related protein needed to induce a humoral- and T-cell-mediated immune response. The application of mRNA to vaccine development emerged as a powerful tool to fight against cancer and non-infectious and infectious diseases, for example, and represents a relevant research field for future decades. Based on these advantages, this review emphasizes mRNA and self-amplifying RNA (saRNA) for vaccine development, mainly to fight against COVID-19, together with the challenges related to this approach.
近年来,使用核糖核酸(RNA)进行疫苗开发已成为生产安全有效的新型疫苗最具前景且研究最多的方法,不仅用于预防,还可用于治疗。与其他平台相比,使用信使核糖核酸(mRNA)作为免疫原在疫苗开发方面具有诸多优势,如成本较低、无需细胞培养以及能够组合不同靶点。在新冠疫情期间,mRNA作为疫苗的应用变得更为重要;全球应用最广泛的四种新冠疫苗中有两种基于这一平台。然而,尽管mRNA技术在疫苗应用方面具有优势,但要提高mRNA的稳定性、递送效率以及产生诱导体液免疫和T细胞介导免疫反应所需相关蛋白质的潜力,仍面临若干关键挑战。例如,mRNA在疫苗开发中的应用已成为对抗癌症、非传染性疾病和传染性疾病的有力工具,并且代表了未来几十年一个相关的研究领域。基于这些优势,本综述重点介绍用于疫苗开发的mRNA和自我扩增RNA(saRNA),主要用于对抗新冠病毒,同时也介绍了与此方法相关的挑战。